Homogeneity of antibody-drug conjugates critically impacts the therapeutic efficacy in brain tumors [article]

Yasuaki Anami, Yoshihiro Otani, Wei Xiong, Summer Y. Y. Ha, Aiko Yamaguchi, Ningyan Zhang, Zhiqiang An, Balveen Kaur, Kyoji Tsuchikama
2021 bioRxiv   pre-print
Glioblastoma multiforme (GBM) is characterized by aggressive growth and the poorest prognosis of all brain tumor types. Most therapies rarely provide clinically meaningful improvements in outcomes of patients with GBM. Antibody-drug conjugates (ADCs) are emerging chemotherapeutics with stunning success in cancer management. Although promising, clinical studies of three ADCs for treating GBM, including Depatux-M, have been discontinued because of safety concerns and limited therapeutic benefits.
more » ... Here, we report that ADC homogeneity is a critical parameter to maximize the therapeutic potential in GBM therapy. We demonstrate that homogeneous conjugates generated using our linker show enhanced drug delivery to intracranial brain tumors. Notably, compared to heterogeneous ADCs, including a Depatux-M analog, our ADCs provide greatly improved antitumor effects and survival benefits in orthotopic brain tumor models, including a patient-derived xenograft model of GBM. Our findings warrant the future development of homogeneous ADCs as promising molecular entities toward cures for intractable brain tumors.
doi:10.1101/2021.12.23.474044 fatcat:cyhajzxiy5g6tl5vqdwevcmqpa